Drug Trial Radar · NCT07459114
TGD001 Treatment in Thrombotic Microangiopathies
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Oct 25, 2026
Primary completion
May 31, 2028
Study completion Aug 30, 2028
Sponsor
- Lead sponsor
- TargED Biopharmaceuticals B.V.Industry
- Sponsor type
- Industry
- First posted
- Mar 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or clinical diagnosis of an acute Thrombotic Microangiopathy (TMA) episode. The trial is an open-label, dose escalation and expansion basket trial.
Conditions
- Thrombotic Microangiopathies
- ITP Immune-Mediated Thrombocytopenia
Interventions
TGD001Drug
IV bolus administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse events (safety and tolerability of TGD001)Time frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
La Fe University and Polytechnic Hospital
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.